| Oct 9 |
Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ...
|
| Sep 23 |
Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers
|
| Aug 31 |
Lantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a Millionaire
|
| Aug 12 |
LTRN: Second Quarter Results
|
| Aug 10 |
Lantern Pharma Inc. 2024 Q2 - Results - Earnings Call Presentation
|
| Aug 10 |
Lantern Pharma Inc. (LTRN) Q2 2024 Earnings Call Transcript
|
| Aug 9 |
Lantern Pharma GAAP EPS of -$0.46 beats by $0.09
|
| Aug 8 |
Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates
|
| Aug 7 |
Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024
|
| Aug 6 |
LTRN: Harmonic Clinical Update
|
